Retinoid treatment of skin diseases

European Journal of Dermatology

Volumn 25, Issue 5, 2015, Pages 384-391

  Beckenbach, Lisa ^a   Baron, Jens M ^b   Merk, Hans F ^b   Löffler, Harald ^a   Amann, Philipp M ^a,b  

^a SLK Clinic Heilbronn GmbH   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Dermatopharmacology; Retinoid therapy; Retinoids; Vitamin A derivatives

Indexed keywords

ADAPALENE; ALITRETINOIN; BEXAROTENE; ETRETIN; ETRETINATE; ISOTRETINOIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR; TAZAROTENE;

ACNE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CENTRAL NERVOUS SYSTEM MALFORMATION; CHEMICAL STRUCTURE; CRANIOFACIAL MALFORMATION; DERMATOLOGY; DERMATOPHARMACOLOGY; DYSKERATOSIS; HUMAN; PSORIASIS; REVIEW; SKIN DISEASE; TREATMENT OUTCOME; FEMALE; MALE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATIENT SAFETY; SKIN DISEASES; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; FEMALE; HUMANS; MALE; PATIENT SAFETY; RETINOIDS; SKIN DISEASES; TREATMENT OUTCOME; TRETINOIN;

EID: 84953847610     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2015.2544     Document Type: Review

References (79)

1. Amann PM, Eichmuller SB, Schmidt J, Bazhin AV. Regulation of gene expression by retinoids. Curr Med Chem 2011; 18: 1405-12.
2. Baron JM, Skazik C, Merk HF. [Retinoids and their metabolism: new therapeutic approaches?]. Hautarzt 2008; 59: 745-6.
3. Baron JM, Merk HF, Bickers DR. Recent studies on the pharmacokinetics and metabolism of retinoids in the skin. In: Vahlquist A, Duvic M, editors. Retinoids and carotenoids in Dermatology. London: Taylor & Francis, 2007, p. 67-75.
4. Stuettgen G. [On the local therapy of keratosis with vitamin A acid]. Dermatologica 1962; 124: 65-80.
5. Kligman AM, Fulton JE Jr., Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol 1969; 99: 469-76.
6. Orfanos CE, Mahrle G, Goerz G, et al. Laboratory investigations in patients with generalized psoriasis under oral retinoid treatment. A multicenter study of computerized data. Dermatologica 1979; 159: 62- 70.
7. Amann PM, Merk HF, Baron JM. [Retinoids in dermatopharmacology]. Hautarzt 2014; 65: 98-105.
8. Baron JM. Retinoid Pharmacology. In: Krieg T, Bickers DR, Miyachi Y, editors. Therapy of Skin Diseases. Berlin Heidelberg: Springer- Verlag, 2010, p. 77-85.
9. Fox LP, Merk HF, Bickers DR. Dermatopharmakologie. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's - Pharmakologische Grundlagen der Arzneimitteltherapie. Berlin:ABW Wissenschaftsverlag GmbH, 2006, p. 1-73.
10. Fisher GJ, Voorhees JJ. Molecular mechanisms of retinoid actions in skin. FASEB J 1996; 10: 1002-13.
11. Dilworth FJ, Chambon P. Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. Oncogene 2001; 20: 3047-54.
12. Mongan NP, Gudas LJ. Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation 2007; 75: 853-70.
13. MacKay D, Miller AL. Nutritional support for wound healing. Altern Med Rev 2003; 8: 359-77.
14. Ndiaye MA, Nihal M, Wood GS, Ahmad N. Skin, reactive oxygen species, and circadian clocks. Antioxid Redox Signal 2014; 20: 2982-96.
15. Hubbard BA, Unger JG, Rohrich RJ. Reversal of skin aging with topical retinoids. Plast Reconstr Surg 2014; 133: 481e-90e.
16. Baron JM, Heise R, Blaner WS, et al. Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol 2005; 125: 143-53.
17. Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005; 174: 2467-70.
18. Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012; 132: 2198-205.
19. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 1998; 134: 884-5.
20. Gollnick H, Blume-Peytavi U, Szabo EL, et al. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges 2010; 8: 505-15.
21. Schaller M, Belge K. [Systemic therapy of rosacea]. Hautarzt 2013; 64: 500-5.
22. Reinholz M, Tietze JK, Kilian K, et al. Rosacea - s1 guideline. J Dtsch Dermatol Ges 2013; 11: 768-80.
23. Rafal ES, Griffiths CE, Ditre CM, et al. Topical tretinoin (retinoic acid) treatment for liver spots associated with photodamage. N Engl J Med 1992; 326: 368-74.
24. Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993; 328: 1438-43.
25. Kang HY, Valerio L, Bahadoran P, Ortonne JP. The role of topical retinoids in the treatment of pigmentary disorders: an evidence-based review. Am J Clin Dermatol 2009; 10: 251-60.
26. Bikowski JB. Mechanisms of the comedolytic and antiinflammatory properties of topical retinoids. J Drugs Dermatol 2005; 4: 41-7.
27. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 2002; 147: 523-7.
28. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998; 139(Suppl 52): 48-56.
29. Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012; 26(Suppl 1): 1-29.
30. Altinyazar HC, Koca R, Tekin NS, Esturk E. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol 2005; 44: 252-5.
31. Heyman RA, Mangelsdorf DJ, Dyck JA, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992; 68: 397-406.
32. Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158: 808-17.
33. Pampin A, Gomez-de la Fuente E, Caro Gutierrez MD, Lopez- Estebaranz JL. Successful treatment of atypical adult pityriasis rubra pilaris with oral alitretinoin. J Am Acad Dermatol 2013; 69: e105-6.
34. Amann P M, Susic M, Gluder F, Berger H, Krapf W, Loffler H. Alitretinoin (9-cis retinoic acid) is Effective Against Pityriasis Rubra Pilaris: A Retrospective Clinical Study. Acta Derm Venereol 2014 Jul 4. doi: 10.2340/00015555-1928. [Epub ahead of print].
35. Barnstedt SE. [Successful treatment of Darier disease with oral alitretinoin]. Hautarzt 2012; 63: 139-41.
36. Letule V, Herzinger T, Ruzicka T, Molin S. Treatment of Darier disease with oral alitretinoin. Clin Exp Dermatol 2013; 38: 523-5.
37. Irla N, Navarini AA, Yawalkar N. Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. Br J Dermatol 2012; 167: 1170-4.
38. Molin S, Ruzicka T. Oral alitretinoin in lichen planus: two case reports. Acta Derm Venereol 2010; 90: 523-4.
39. Brehmer F, Haenssle HA, Schon MP, Emmert S. Response of recalcitrant lichen planus to alitretinoin in 3 patients. J Am Acad Dermatol 2011; 65: e58-60.
40. Alsenaid A, Eder I, Ruzicka T, Braun-Falco M, Wolf R. Successful treatment of nail lichen planus with alitretinoin: report of 2 cases and review of the literature. Dermatology 2014; 229: 293-6.
41. Kolesnik M, Gollnick H, Bonnekoh B. Complete remission of alopecia areata under treatment of chronic hand eczema with alitretinoin. Eur J Dermatol 2013; 23: 110-1.
42. Molin S, Ruzicka T. Possible benefit of oral alitretinoin in T-lymphoproliferative diseases: a report of two patients with palmoplantar hyperkeratotic-rhagadiform skin changes and mycosis fungoides or Sezary syndrome. Br J Dermatol 2009; 161: 1420-2.
43. Kapser C, Herzinger T, Ruzicka T, Flaig M, Molin S. Treatment of cutaneous T-cell lymphoma with oral alitretinoin. J Eur Acad Dermatol Venereol 2014.
44. Ganemo A, Sommerlund M, Vahlquist A. Oral alitretinoin in congenital ichthyosis: a pilot study shows variable effects and a risk of central hypothyroidism. Acta Derm Venereol 2012; 92: 256-7.
45. Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE,Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999; 22: 235- 46.
46. Baumann L, Vujevich J, Halem M, et al. Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis 2005; 76: 69-73.
47. Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269-71.
48. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl 2): 1-70.
49. Ormerod AD, Campalani E, Goodfield MJ. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010; 162: 952-63.
50. Schadt CR. Topical and oral bexarotene. Dermatol Ther 2013; 26: 400-3.
51. Stadler R, Assaf C, Klemke CD, et al. Brief S2k guidelines- Cutaneous lymphomas. J Dtsch Dermatol Ges 2013; 11(Suppl 3), 19-28, 0-30.
52. Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 2013; 168: 192-200.
53. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002; 138: 325-32.
54. Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 2003; 49: 801-15.
55. Hanifin JM, Stevens V, Sheth P, Breneman D. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol 2004; 150: 545-53.
56. Breneman D, Sheth P, Berger V, Naini V, Stevens V. Phase II clinical trial of bexarotene gel 1% in psoriasis. J Drugs Dermatol 2007; 6: 501-6.
57. Magliocco MA, Pandya K, Dombrovskiy V, Christiansen L,Wong Y, Gottlieb AB. A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2006; 54: 115-8.
58. Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol 2009; 61: 592 e1-9.
59. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002; 146: 351-64.
60. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001; 68: 355-8.
61. Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 2003; 149: 207-9.
62. Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. Acta Derm Venereol 2007; 87: 167-8.
63. Moriarty M, Dunn J, Darragh A, Lambe R, Brick I. Etretinate in treatment of actinic keratosis. A double-blind crossover study. Lancet 1982; 1: 364-5.
64. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-7.
65. Shuttleworth D, Marks R, Griffin PJ, Salaman JR. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988; 68: 717-25.
66. Euvrard S, Verschoore M, Touraine JL, et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet 1992; 340: 48-9.
67. Wu PA, Stern RS. Topical tretinoin, another failure in the pursuit of practical chemoprevention for non-melanoma skin cancer. J Invest Dermatol 2012; 132: 1532-5.
68. Weinstock MA, Bingham SF, Digiovanna JJ, et al. Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 2012; 132: 1583-90.
69. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005; 152: 518-23.
70. Lens M, Medenica L. Systemic retinoids in chemoprevention of non-melanoma skin cancer. Expert Opin Pharmacother 2008; 9: 1363-74.
71. Kadakia KC, Barton DL, Loprinzi CL, et al. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer 2012; 118: 2128-37.
72. Bavinck JN, Tieben LM, Van derWoude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933-8.
73. George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43: 269-73.
74. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837-41.
75. Larsen FG, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen-Kudsk F. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993; 100: 623-7.
76. Nohynek GJ, Meuling WJ, Vaes WH, et al. Repeated topical treatment, in contrast to single oral doses, with Vitamin A-containing preparations does not affect plasma concentrations of retinol, retinyl esters or retinoic acids in female subjects of child-bearing age. Toxicol Lett 2006; 163: 65-76.
77. Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A 2005; 136: 117-21.
78. DiGiovanna JJ. Retinoid chemoprevention in the high-risk patient. J Am Acad Dermatol 1998; 39: S82-5.
79. Sherman SI. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin Lymphoma 2003; 3: 249-52.